Record quarter, falling shares: what is really happening with Intuitive Surgical
Intuitive Surgical $ISRG increased revenue by 19% to $2.89 billion in the second quarter of 2026 and non-GAAP earnings per share by 28% to $2.80, significantly above analysts' estimates ($2.51). Yet the stock fell more than 12% immediately after the results were released on July 16, trading below its 52-week low. The reason was not the quarter itself but slowing procedure growth in the U.S. and an outlook that management did not raise despite record numbers.
Key points
Record quarter, falling shares. For Q2 2026, it beat earnings and revenue estimates (EPS $2.80 vs. consensus $2.51, revenue $2.89 billion), yet the stock plunged more than 12% due to U.S. procedure growth slowing to 12% from 14%.
ACA subsidies and GLP-1 drugs as specific headwinds. Management says the slowdown is due to a combination of deferred care because of changes in Affordable Care Act subsidies and the continued decline in bariatric surgeries due to increasing use of GLP-1 weight-loss drugs.
Strong balance sheet and growing profitability. The company is debt-free, holds $8.6 billion in cash, free cash flow increased 71% year-over-year, and net margin has risen from 21% to 28% over the past four years.
Competition is waking up. Medtronic is expanding its Hugo beyond urology, Johnson & Johnson is preparing Ottava, and for the first time in more than twenty years Intuitive faces real competition in its home market.
Valuation remains above the sector even after the drop. Forward P/E around 33x is roughly 70% above the medical device median, so even after the correction the stock carries the risk of further multiple compression if the U.S. slowdown proves more lasting.
The market thus sent a clear signal: for a company valued at tens of times earnings, beating estimates is no longer enough if there is even a hint of a slowdown in the key U.S. market. U.S. procedure growth slowing to 12% from 14% in the prior quarter, concerns about the impact of changes in Affordable Care Act subsidies, and the growing influence of weight-loss drugs on the number of bariatric surgeries are the specific reasons why investors overlooked otherwise strong numbers. The question remains to what extent this is a temporary slowdown and to what extent it is a sign that the U.S. robotic surgery market is approaching maturity.
A robot that charges for every cut
Intuitive manufactures and sells robotic systems for minimally invasive surgery, the best known being the da Vinci platform, with which doctors operate from a console controlling robotic arms with surgical instruments inside the patient's body. In addition to da Vinci, the company also offers Ion, a robotic system for diagnosing lung cancer that inserts a flexible probe into lung tissue. The company does not make money primarily from selling the robots themselves, but mainly from recurring revenue from disposable surgical instruments, accessories, and service, which hospitals buy for each individual operation. The more operations performed on the installed systems, the higher the recurring revenue, which is why tracking the procedure growth rate, not just the number of systems sold, is key to understanding the business.
Why the market punished a company that beat estimates
At first glance, the market's reaction seems illogical. Intuitive beat earnings estimates by almost 12% and revenue by 2.5%, yet the stock experienced one of its worst days in history. The key to understanding lies in the U.S. procedure growth rate, because it is precisely these that drive recurring revenue from instruments and accessories, which make up the bulk of the business.
Finish the whole article on MDT
And you also unlock fair value and more tools
Black membership: analyses, screener, newsletters and unlimited StockBot.